Influenza Drug Market (By Type: Antiviral Medications, Vaccines, Immunomodulators, Symptomatic Treatments, Combination Therapies; By Mechanism of Action: Neuraminidase Inhibitors, Cap-dependent Endonuclease Inhibitors, Fusion Inhibitors, M2 Ion Channel Inhibitors, Host Cell Protease Inhibitors, Immunomodulatory Agents, RNA Polymerase Inhibitors, Others; By Route of Administration; By End user) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Influenza Drug Market 

5.1. COVID-19 Landscape: Influenza Drug Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Influenza Drug Market, By Type

8.1. Influenza Drug Market Revenue and Volume Forecast, by Type, 2024-2033

8.1.1. Antiviral Medications

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Vaccines

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Immunomodulators

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Symptomatic Treatments

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Combination Therapies

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Influenza Drug Market, By Mechanism of Action

9.1. Influenza Drug Market Revenue and Volume Forecast, by Mechanism of Action, 2024-2033

9.1.1. Neuraminidase Inhibitors

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Cap-dependent Endonuclease Inhibitors

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Fusion Inhibitors

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. M2 Ion Channel Inhibitors

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Host Cell Protease Inhibitors

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Immunomodulatory Agents

9.1.6.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. RNA Polymerase Inhibitors

9.1.7.1. Market Revenue and Volume Forecast (2021-2033)

9.1.8. Hemagglutinin Stem Binders

9.1.8.1. Market Revenue and Volume Forecast (2021-2033)

9.1.9. Cytokine Inhibitors

9.1.9.1. Market Revenue and Volume Forecast (2021-2033)

9.1.10. Host Factor Targeting

9.1.10.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Influenza Drug Market, By Route of Administration 

10.1. Influenza Drug Market Revenue and Volume Forecast, by Route of Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Intranasal

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Intravenous

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Intramuscular

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

10.1.5. Subcutaneous

10.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Influenza Drug Market, By End-user 

11.1. Influenza Drug Market Revenue and Volume Forecast, by End-user, 2024-2033

11.1.1. Hospitals and Clinics

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Pharmacies

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Vaccination Centers

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

11.1.4. Research Institutions

11.1.4.1. Market Revenue and Volume Forecast (2021-2033)

11.1.5. Government Health Agencies

11.1.5.1. Market Revenue and Volume Forecast (2021-2033)

11.1.6. Long-term Care Facilities

11.1.6.1. Market Revenue and Volume Forecast (2021-2033)

11.1.7. Community Health Centers

11.1.7.1. Market Revenue and Volume Forecast (2021-2033)

11.1.8. Corporate Health Programs

11.1.8.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Influenza Drug Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.1.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.1.5.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.5.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.1.6.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.6.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.2.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.5.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.5.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.6.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.6.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.7.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.7.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.8.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.8.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.3.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.5.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.5.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.6.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.6.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.7.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.7.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.8.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.8.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.5.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.5.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.6.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.6.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.7.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.7.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.8.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.8.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.5.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.5.5.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.5.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

12.5.6.2. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2033)

12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.6.4. Market Revenue and Volume Forecast, by End-user (2021-2033)

Chapter 13. Company Profiles

13.1. Daiichi Sankyo Company

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GlaxoSmithKline

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Natco Pharma

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. F. Hoffmann-La Roche

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Teva Pharmaceutical

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Sandoz International

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Sun Pharmaceutical Industries

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Mylan

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY :

   USD 5400
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample